Antibody and Recombinant Protein CDMO Market

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Antibody CDMO
1.2.3 Recombinant Protein CDMO
1.3 Market by Application
1.3.1 Global Antibody and Recombinant Protein CDMO Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Generic Company
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Antibody and Recombinant Protein CDMO Market Perspective (2017-2028)
2.2 Antibody and Recombinant Protein CDMO Growth Trends by Region
2.2.1 Antibody and Recombinant Protein CDMO Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Antibody and Recombinant Protein CDMO Historic Market Size by Region (2017-2022)
2.2.3 Antibody and Recombinant Protein CDMO Forecasted Market Size by Region (2023-2028)
2.3 Antibody and Recombinant Protein CDMO Market Dynamics
2.3.1 Antibody and Recombinant Protein CDMO Industry Trends
2.3.2 Antibody and Recombinant Protein CDMO Market Drivers
2.3.3 Antibody and Recombinant Protein CDMO Market Challenges
2.3.4 Antibody and Recombinant Protein CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody and Recombinant Protein CDMO Players by Revenue
3.1.1 Global Top Antibody and Recombinant Protein CDMO Players by Revenue (2017-2022)
3.1.2 Global Antibody and Recombinant Protein CDMO Revenue Market Share by Players (2017-2022)
3.2 Global Antibody and Recombinant Protein CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antibody and Recombinant Protein CDMO Revenue
3.4 Global Antibody and Recombinant Protein CDMO Market Concentration Ratio
3.4.1 Global Antibody and Recombinant Protein CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody and Recombinant Protein CDMO Revenue in 2021
3.5 Antibody and Recombinant Protein CDMO Key Players Head office and Area Served
3.6 Key Players Antibody and Recombinant Protein CDMO Product Solution and Service
3.7 Date of Enter into Antibody and Recombinant Protein CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody and Recombinant Protein CDMO Breakdown Data by Type
4.1 Global Antibody and Recombinant Protein CDMO Historic Market Size by Type (2017-2022)
4.2 Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Type (2023-2028)
5 Antibody and Recombinant Protein CDMO Breakdown Data by Application
5.1 Global Antibody and Recombinant Protein CDMO Historic Market Size by Application (2017-2022)
5.2 Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Antibody and Recombinant Protein CDMO Market Size (2017-2028)
6.2 North America Antibody and Recombinant Protein CDMO Market Size by Country (2017-2022)
6.3 North America Antibody and Recombinant Protein CDMO Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Antibody and Recombinant Protein CDMO Market Size (2017-2028)
7.2 Europe Antibody and Recombinant Protein CDMO Market Size by Country (2017-2022)
7.3 Europe Antibody and Recombinant Protein CDMO Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size (2017-2028)
8.2 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Country (2017-2022)
8.3 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Antibody and Recombinant Protein CDMO Market Size (2017-2028)
9.2 Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2017-2022)
9.3 Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size (2017-2028)
10.2 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2017-2022)
10.3 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Batavia Biosciences
11.1.1 Batavia Biosciences Company Detail
11.1.2 Batavia Biosciences Business Overview
11.1.3 Batavia Biosciences Antibody and Recombinant Protein CDMO Introduction
11.1.4 Batavia Biosciences Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.1.5 Batavia Biosciences Recent Development
11.2 Grifols
11.2.1 Grifols Company Detail
11.2.2 Grifols Business Overview
11.2.3 Grifols Antibody and Recombinant Protein CDMO Introduction
11.2.4 Grifols Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.2.5 Grifols Recent Development
11.3 Cerbios-Pharma SA
11.3.1 Cerbios-Pharma SA Company Detail
11.3.2 Cerbios-Pharma SA Business Overview
11.3.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Introduction
11.3.4 Cerbios-Pharma SA Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.3.5 Cerbios-Pharma SA Recent Development
11.4 HALIX
11.4.1 HALIX Company Detail
11.4.2 HALIX Business Overview
11.4.3 HALIX Antibody and Recombinant Protein CDMO Introduction
11.4.4 HALIX Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.4.5 HALIX Recent Development
11.5 Biovian Oy
11.5.1 Biovian Oy Company Detail
11.5.2 Biovian Oy Business Overview
11.5.3 Biovian Oy Antibody and Recombinant Protein CDMO Introduction
11.5.4 Biovian Oy Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.5.5 Biovian Oy Recent Development
11.6 Catalent
11.6.1 Catalent Company Detail
11.6.2 Catalent Business Overview
11.6.3 Catalent Antibody and Recombinant Protein CDMO Introduction
11.6.4 Catalent Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.6.5 Catalent Recent Development
11.7 Goodwin Biotechnology
11.7.1 Goodwin Biotechnology Company Detail
11.7.2 Goodwin Biotechnology Business Overview
11.7.3 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Introduction
11.7.4 Goodwin Biotechnology Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.7.5 Goodwin Biotechnology Recent Development
11.8 Merck
11.8.1 Merck Company Detail
11.8.2 Merck Business Overview
11.8.3 Merck Antibody and Recombinant Protein CDMO Introduction
11.8.4 Merck Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.8.5 Merck Recent Development
11.9 Hangzhou Hs-biopharm
11.9.1 Hangzhou Hs-biopharm Company Detail
11.9.2 Hangzhou Hs-biopharm Business Overview
11.9.3 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Introduction
11.9.4 Hangzhou Hs-biopharm Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.9.5 Hangzhou Hs-biopharm Recent Development
11.10 Wuxibiologics
11.10.1 Wuxibiologics Company Detail
11.10.2 Wuxibiologics Business Overview
11.10.3 Wuxibiologics Antibody and Recombinant Protein CDMO Introduction
11.10.4 Wuxibiologics Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.10.5 Wuxibiologics Recent Development
11.11 Bioinnobio
11.11.1 Bioinnobio Company Detail
11.11.2 Bioinnobio Business Overview
11.11.3 Bioinnobio Antibody and Recombinant Protein CDMO Introduction
11.11.4 Bioinnobio Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.11.5 Bioinnobio Recent Development
11.12 Thousand Oaks Biopharmaceuticals
11.12.1 Thousand Oaks Biopharmaceuticals Company Detail
11.12.2 Thousand Oaks Biopharmaceuticals Business Overview
11.12.3 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Introduction
11.12.4 Thousand Oaks Biopharmaceuticals Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.12.5 Thousand Oaks Biopharmaceuticals Recent Development
11.13 Cerbios-Pharma SA
11.13.1 Cerbios-Pharma SA Company Detail
11.13.2 Cerbios-Pharma SA Business Overview
11.13.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Introduction
11.13.4 Cerbios-Pharma SA Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.13.5 Cerbios-Pharma SA Recent Development
11.14 Eurogentec
11.14.1 Eurogentec Company Detail
11.14.2 Eurogentec Business Overview
11.14.3 Eurogentec Antibody and Recombinant Protein CDMO Introduction
11.14.4 Eurogentec Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.14.5 Eurogentec Recent Development
11.15 HJB
11.15.1 HJB Company Detail
11.15.2 HJB Business Overview
11.15.3 HJB Antibody and Recombinant Protein CDMO Introduction
11.15.4 HJB Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.15.5 HJB Recent Development
11.16 Bibo Pharma
11.16.1 Bibo Pharma Company Detail
11.16.2 Bibo Pharma Business Overview
11.16.3 Bibo Pharma Antibody and Recombinant Protein CDMO Introduction
11.16.4 Bibo Pharma Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.16.5 Bibo Pharma Recent Development
11.17 MabPlex International
11.17.1 MabPlex International Company Detail
11.17.2 MabPlex International Business Overview
11.17.3 MabPlex International Antibody and Recombinant Protein CDMO Introduction
11.17.4 MabPlex International Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.17.5 MabPlex International Recent Development
11.18 Genscriptprobio
11.18.1 Genscriptprobio Company Detail
11.18.2 Genscriptprobio Business Overview
11.18.3 Genscriptprobio Antibody and Recombinant Protein CDMO Introduction
11.18.4 Genscriptprobio Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.18.5 Genscriptprobio Recent Development
11.19 Vetter
11.19.1 Vetter Company Detail
11.19.2 Vetter Business Overview
11.19.3 Vetter Antibody and Recombinant Protein CDMO Introduction
11.19.4 Vetter Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.19.5 Vetter Recent Development
11.20 Etinpro (Beijing) Co
11.20.1 Etinpro (Beijing) Co Company Detail
11.20.2 Etinpro (Beijing) Co Business Overview
11.20.3 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Introduction
11.20.4 Etinpro (Beijing) Co Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.20.5 Etinpro (Beijing) Co Recent Development
11.21 Boehringer Ingelheim BioXcellence
11.21.1 Boehringer Ingelheim BioXcellence Company Detail
11.21.2 Boehringer Ingelheim BioXcellence Business Overview
11.21.3 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Introduction
11.21.4 Boehringer Ingelheim BioXcellence Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.21.5 Boehringer Ingelheim BioXcellence Recent Development
11.22 Lonza
11.22.1 Lonza Company Detail
11.22.2 Lonza Business Overview
11.22.3 Lonza Antibody and Recombinant Protein CDMO Introduction
11.22.4 Lonza Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.22.5 Lonza Recent Development
11.23 3SBio Inc
11.23.1 3SBio Inc Company Detail
11.23.2 3SBio Inc Business Overview
11.23.3 3SBio Inc Antibody and Recombinant Protein CDMO Introduction
11.23.4 3SBio Inc Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.23.5 3SBio Inc Recent Development
11.24 Porton
11.24.1 Porton Company Detail
11.24.2 Porton Business Overview
11.24.3 Porton Antibody and Recombinant Protein CDMO Introduction
11.24.4 Porton Revenue in Antibody and Recombinant Protein CDMO Business (2017-2022)
11.24.5 Porton Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details